Analysis Tools
neoplasm
|
• changes in leukocyte numbers are consistent with a chronic myelomonocytic leukemia (CMML)-like disease
• transplantation of bone marrow cells into lethally irradiated congenic wild-type mice followed by tamoxifen treatment also results in a CMML-like disease
|
hematopoietic system
|
• seen in all mice 4 weeks after the last tamoxifen injection
|
|
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
|
|
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
|
|
• 4 weeks after the last tamoxifen injection
|
|
• signs of erythroid dysplasia after tamoxifen treatment
• prominent basophilic stippling after tamoxifen treatment
|
|
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with ineffective erythropoiesis
|
|
• after tamoxifen treatment
|
|
• after tamoxifen treatment
|
|
• bilobed granulocytes after tamoxifen treatment
|
|
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
|
|
• 4 weeks after the last tamoxifen injection
|
|
• detected as early as 1 week after the last tamoxifen treatment
|
|
• giant platelets detected after tamoxifen treatment
|
|
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
|
|
• 4 weeks after the last tamoxifen injection
|
|
• in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
|
|
• cells taken from tamoxifen treated mice fail to reconstitute the bone marrow of lethally irradiated congenic wild-type mice
|
|
• cultured cells collected 1 month after the last tamoxifen treatment produce fewer colonies and replated cells do not produce well formed colonies
|
immune system
|
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment
|
|
• seen in all mice 4 weeks after the last tamoxifen injection
|
|
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
|
|
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
|
|
• bilobed granulocytes after tamoxifen treatment
|
|
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
|
|
• 4 weeks after the last tamoxifen injection
|
|
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
|
|
• 4 weeks after the last tamoxifen injection
|
homeostasis/metabolism
|
• microthrombi in the heart after tamoxifen treatment
|
muscle
|
• multifocal necrosis after tamoxifen treatment
|
cardiovascular system
|
• multifocal necrosis after tamoxifen treatment
|
|
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment
|
growth/size/body
|
• seen in all mice 4 weeks after the last tamoxifen injection
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| myelodysplastic syndrome | DOID:0050908 |
OMIM:614286 |
J:187380 | |
